Granulo-monocyto apheresis is more effective in mild ulcerative colitis than in moderate to severe disease

被引:4
作者
De Cassan, Chiara [1 ]
Savarino, Edoardo [1 ]
Marson, Piero [2 ]
Tison, Tiziana [2 ]
Hatem, Giorgia [1 ]
Sturniolo, Giacomo Carlo [1 ]
D'Inca, Renata [1 ]
机构
[1] Univ Padua, Dept Surg Oncol & Gastroenterol, Div Gastroenterol, I-35128 Padua, Italy
[2] Univ Padua, Blood Transfus Serv, Apheresis Unit, I-35128 Padua, Italy
关键词
Ulcerative colitis; Granulo-monocyto-apheresis; Inflammatory bowel disease; Therapy; Severity; INFLAMMATORY-BOWEL-DISEASE; RANDOMIZED CONTROLLED-TRIAL; CARRIER-BASED GRANULOCYTE; QUALITY-OF-LIFE; SELECTIVE LEUKOCYTAPHERESIS; 5-AMINOSALICYLIC ACID; ADSORPTIVE APHERESIS; PREDICTIVE FACTORS; EFFICACY; THERAPY;
D O I
10.3748/wjg.v20.i45.17155
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To evaluate whether the effectiveness of Granulomonocyto apheresis (GMA), a technique that consists of the extracorporeal removal of granulocytes and monocytes from the peripheral blood, might vary according to the severity of ulcerative colitis (UC) in patients with mild to moderate-severe disease UC activity. METHODS: We retrospectively reviewed prospectively collected data of patients undergoing GMA at our inflammatory bowel disease centre who had at least a 6 mo of follow-up. The demographics, clinical and laboratory data were extracted from the patients' charts and electronic records. The severity of UC was scored according to the Modified Truelove Witts Severity Index (MTWSI). A clinical response was defined as a decrease from baseline of >= 2 points or a value of MTWSI <= 2 points. RESULTS: A total of 41 (24 males/17 females; mean age 47 years) patients were included in the study. After GMA cycle completion, 21/28 (75%) of mild UC patients showed a clinical response compared with 7/13 (54%) of patients with moderate to severe disease (P = 0.27). At 6-mo, 14/28 (50%) of the mild UC patients maintained a clinical response compared with 2/13 (15%) of the patients with moderate to severe disease (P = 0.04). After the GMA cycle completion and during the 6-mo follow up period, 13/16 (81%) and 9/16 (56%) of mild UC patients with intolerance, resistance and contraindications to immunosuppressants and/or biologics showed a clinical response compared with 2/6 (33%) and 0/6 (0%) of patients with moderate to severe disease activity with these characteristics (P = 0.05 and P = 0.04, respectively). CONCLUSION: Patients with mild UC benefit from GMA more than patients with moderate to severe disease in the short-term period. GMA should be considered a valid therapeutic option in cases of contraindications to immunosuppressants, corticosteroids and/or biologics. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.
引用
收藏
页码:17155 / 17162
页数:8
相关论文
共 52 条
  • [1] Corticosteroids and immunomodulators: Postoperative infectious complication risk in inflammatory bowel disease patients
    Aberra, FN
    Lewis, JD
    Hass, D
    Rombeau, JL
    Osborne, B
    Lichtenstein, GR
    [J]. GASTROENTEROLOGY, 2003, 125 (02) : 320 - 327
  • [2] Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis
    Ardizzone, S
    Maconi, G
    Russo, A
    Imbesi, V
    Colombo, E
    Porro, GB
    [J]. GUT, 2006, 55 (01) : 47 - 53
  • [3] Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis
    Arts, J
    D'Haens, G
    Zeegers, M
    Van Assche, G
    Hiele, M
    D'Hoore, A
    Penninckx, F
    Vermeire, S
    Rutgeerts, P
    [J]. INFLAMMATORY BOWEL DISEASES, 2004, 10 (02) : 73 - 78
  • [4] Treatment of patients with acute ulcerative colitis: Conventional corticosteroid therapy (MP) versus granulocytapheresis (GMA): A pilot study
    Bresci, G.
    Parisi, G.
    Mazzoni, A.
    Scatena, F.
    Capria, A.
    [J]. DIGESTIVE AND LIVER DISEASE, 2007, 39 (05) : 430 - 434
  • [5] Granulocytapheresis versus methylprednisolone in patients with acute ulcerative colitis: 12-month follow up
    Bresci, Giampaolo
    Parisi, Giuseppe
    Mazzoni, Alessandro
    Scatena, Fabrizio
    Capria, Alfonso
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2008, 23 (11) : 1678 - 1682
  • [6] Leukocytapheresis as promising therapy for inflammatory bowel disease
    Caprilli, R.
    D'Ovidio, V.
    [J]. DIGESTIVE AND LIVER DISEASE, 2007, 39 (05) : 435 - 437
  • [7] Impairment of health-related quality of life in patients with inflammatory bowel disease:: A Spanish multicenter study
    Casellas, F
    Arenas, JI
    Baudet, JS
    Fábregas, S
    García, N
    Gelabert, J
    Medina, C
    Ochotorena, I
    Papo, M
    Rodrigo, L
    Malagelada, JR
    [J]. INFLAMMATORY BOWEL DISEASES, 2005, 11 (05) : 488 - 496
  • [8] Connolly MP, 2014, J CROHNS COLITIS, V8, P357, DOI 10.1016/j.crohns.2013.09.015
  • [9] Regulatory T cells in patients with inflammatory bowel diseases treated with adacolumn granulocytapheresis
    Cuadrado, Emilio
    Alonso, Marta
    de Juan, Maria Dolores
    Echaniz, Pilar
    Arenas, Juan Ignacio
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (10) : 1521 - 1527
  • [10] Predictive factors of clinical response in steroid-refractory ulcerative colitis treated with granulocyte-monocyte apheresis
    D'Ovidio, Valeria
    Meo, Donatella
    Viscido, Angelo
    Bresci, Giampaolo
    Vernia, Piero
    Caprilli, Renzo
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2011, 17 (14) : 1831 - 1835